Enabling Protein Degradation Drug Discovery

Home » News & Events

Stemgent announces formation of Ubiquigent, a new UK-listed biotechnology company based in Dundee, Scotland

Posted on March 3rd, 2010 in News
New Venture co-founded with Professor Sir Philip Cohen to Focus on the Ubiquitin Proteasome Pathway, a Key Cell Signalling System with Significant Drug Discovery Potential Boston, MA, San Diego, CA, USA, March 3, 2010 - Stemgent, Inc., a biotechnology company… Read more